Virological Outcomes of EVG/COBI/FTC/TDF and EVG/COBI/FTC/TAF in Antiretroviral-Naive HIV-1-Infected Participants with Baseline HIV-1 RNA ≥1,000,000 Copies/ml: A Post Hoc Analysis of Phase III Clinical Trials

Adams J.L. , Byrne D. , Pepe R. , Gray A. , Baxter J.D. Virological failure in two patients with HIV-1 RNA viral loads >1,000,000 copies/ml initiated on elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate. Antivir Ther 2016; 21: 175–180.

Sax P.E. , DeJesus E. , Mills A. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, Phase 3 trial, analysis of results after 48 weeks. Lancet 2012; 379: 2439–2448.

Zolopa A. , Sax P.E. , DeJesus E. A randomized double-blind comparison of coformulated elvitegravir/cobicistat/ emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr 2013; 63: 96–100.

Wohl D.A. , Cohen C. , Gallant J.E. A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. J Acquir Immune Defic Syndr 2014; 65: e118–121.

DeJesus E. , Rockstroh J. , Henry K. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, Phase 3, non-inferiority trial. Lancet 2012; 379: 2429–2438.

Rockstroh J.K. , DeJesus E. , Henry K. Randomized, double-blind comparison of coformulated elvitegravir/ cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr 2013; 62: 483–486.

Clumeck N. , Molina J.M. , Henry K. A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. J Acquir Immune Defic Syndr 2014; 65: e121–124.

Sax P.E. , Wohl D. , Yin M.T. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, Phase 3, non-inferiority trials. Lancet 2015; 385: 2606–2615.

Wohl D. , Oka S. , Clumeck N. Brief report: a randomized, double-blind comparison of tenofovir alafenamide versus tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine for initial HIV-1 treatment: week 96 results. J Acquir Immune Defic Syndr 2016; 72: 58–64.

Squires K. , Kityo C. , Hodder S. Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, Phase 3 study. Lancet HIV 2016; 3: e410–e420.

White K.L. , Raff F. , Miller M.D. Resistance analyses of integrase strand transfer inhibitors within Phase 3 clinical trials of treatment-naive patients. Viruses 2014; 6: 2858–2879.

Chao C. , Tang B. , Hurley L. Risk factors for short-term virologic outcomes among HIV-infected patients undergoing regimen switch of combination antiretroviral therapy. AIDS Res Hum Retroviruses 2012; 28: 1630–1636.

Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Developed by the DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents – A Working Group of the Office of AIDS Research Advisory Council (OARAC). (Updated 14 July 2016. Accessed 14 July 2016.) Available from http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.

Lepik K.J. , Harrigan P.R. , Yip B. Emergent drug resistance with integrase strand transfer inhibitor-based regimens. AIDS 2017; 31: 1425–1434.

Krawczyk C.S. , Funkhouser E. , Kilby J.M. , Vermund S.H. Delayed access to HIV diagnosis and care: special concerns for the southern United States. AIDS Care 2006; 18 Suppl 2: S35–S44.

Mbuagbaw L. , Sivaramalingam B. , Navarro T. Interventions for enhancing adherence to antiretroviral therapy (ART): a systematic review of high quality studies. AIDS Patient Care STDS 2015; 29: 248–266.